Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
OncoMethylome Sciences (EBR:ONCOB) Liege (Belgium) - Regulatory Release - September 12, 2008, 8:00 CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) publishes required information in accordance with new transparency legislation (Belgian Act of May 2, 2007) on disclosure of major holdings in issuers whose shares are admitted to trading on a regulated Belgian market.
Status as of 1 September 2008
Basic data
Total capital: EUR 48 362 545.64 Total number of securities conferring voting rights: 11 808 822 shares Total number of voting rights (the denominator): 11 808 822 (one voting right per share)
Supplementary data
Total number of bonds convertible into securities conferring voting rights: zero
Total number of outstanding warrants convertible into securities conferring voting rights: 248,959
Total number of voting rights that may result form the exercise of outstanding warrants: 448,895
Total number of shares without voting rights: zero
Notification thresholds set by the Articles of Association
According to article 14 of articles of association of OncoMethylome Sciences SA, the provisions of articles 6 through 17 of the Act of May 2, 2007 apply not only to the legal thresholds of 5 % and of each multiple of 5%, but also to the threshold of 3%.
Information concerning the transparency legislation
Detailed information concerning the transparency legislation can be found in the Extract from the "Guide to the Transparency Legislation CBFA_2008_16 of 8 July 2008" which is available from the website of the Banking, Finance and Insurance Commission (CBFA): www.cbfa.be/eng/gv/ah/circ/pdf/cbfa_2008_16.pdf
For submitting the notifications the CBFA recommends the use of its standard form TR-1 BE, which is also available from the CBFA website: www.cbfa.be/eng/gv/ah/circ/pdf/TR-1BE.xls
The notifications should be transmitted to both OncoMethylome Sciences SA and the CBFA. The CBFA recommends transmitting the notifications first electronically, to the e-mail address trp.fin@cbfa.be, and subsequently - for reasons of legal certainty - by fax to number + 32 2 220 59 12.
It is recommended to transmit notifications to OncoMethylome Sciences SA to the attention of:
Mr. Philip Devine, CFO E-mail address: ir@oncomethylome.com Fax: +32 4 364 20 84
To download this press release as PDF, click here: Press Release PDF
About OncoMethylome Sciences
OncoMethylome Sciences SA (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.
OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Merck KGaA, and Millipore Corporation's BioScience Division. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).
Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).
For more information please contact: Lucija Turcinov Tel. +32-479-801-902 ir@oncomethylome.com or visit: www.oncomethylome.com
